Company Details
  • Taizhou Volsen Chemical Co., Ltd.

  •  [Zhejiang,China]
  • Business Type:Manufacturer
  • Main Mark: Americas , Asia , East Europe , Europe , North Europe , Other Markets , West Europe , Worldwide
  • Exporter:91% - 100%
  • Certs:GS, CE, ISO9001, ISO14000
  • Description:BSF 208075 BSF208075 Ambrisentan CAS 177036-94-1,What Is Ambrisentan 177036-94-1 UUsed for,ETA Antagonis Ambrisentan 177036-94-1
Taizhou Volsen Chemical Co., Ltd. BSF 208075 BSF208075 Ambrisentan CAS 177036-94-1,What Is Ambrisentan 177036-94-1 UUsed for,ETA Antagonis Ambrisentan 177036-94-1
Home > Products > Active Pharmaceutical Ingredients > Pulmonary Hypertension Treatment Ambrisentan 177036-94-1

Pulmonary Hypertension Treatment Ambrisentan 177036-94-1

Share to:  
    Unit Price: USD 1 / Kilogram
    Payment Type: L/C,T/T
    Min. Order: 1 Kilogram
    Delivery Time: 15 Days

Basic Info

Model No.: 177036-94-1

Additional Info

Packaging: AS REQUIRED

Productivity: 10KGS/M

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: UNLIMITED

Certificate: ISO

Product Description

Ambrisentan cas number 177036-94-1 is an endothelin receptor antagonist, clinically suitable for the treatment of pulmonary hypertension. There are currently three types of endothelin receptor antagonists listed: bosentan, Sitaxentan sodium and Ambrisentan . The effect of bosentan and Sitaxentan sodium was not satisfactory, and patients taking Sitaxentan or bosentan had a higher incidence of abnormal liver function, resulting in elevated blood transaminase levels. This adverse reaction can generally reduce the dose or temporary withdrawal control, but the patient must be regular monitoring, if necessary, to be permanently discontinued. The combination of sitaxentan and warfarin in the treatment of pulmonary hypertension has interaction effect. While Ambrisentan is not the interaction with warfarin when combined together., so Ambrisentan cas number 177036-94-1 has obvious advantages in pulmonary hypertension treatment. Ambrisentan cas number 177036-94-1 by oral administration, can quickly absorb into the body cycle, with a high bioavailability, food does not affect its bioavailability. Give only one a day. Clinical trials show that Ambrisentan has good safety and tolerance. In the phase II clinical trial, the adverse effects of patients taking Ambrisentan 177036-94-1were mildly swollen, upper respiratory tract infection, epistaxis, headache, nausea, vomiting, and no dose-dependent. In the long-term use of Ambrisentan patients, taking Ambrisentan till one year, no emergency safety incidents.


Thera. Category:Pulmonary Hypertension Treatment
Cas No.:177036-94-1
Synonym: BSF 208075, AMBRISENTAN;2-(4,6-Dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid;(aS)-a-[(4,6-Dimethyl-2-pyrimidinyl)oxy]--methoxy--phenylbenzenepropanoic Acid;BSF 208075;LU 208075,bsf-208075

177036-94-1
Molecular Formula:C22H22N2O4
Molecular Weight:378.42
Pharmacopeia: in house spe.
Specifications:Available on request
Packing:Export worthy packing
Material Safety Data Sheet:Available on request

Looking for ideal BSF 208075 BSF208075 Ambrisentan CAS 177036-94-1 Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the What Is Ambrisentan 177036-94-1 UUsed for are quality guaranteed. We are China Origin Factory of ETA Antagonis Ambrisentan 177036-94-1. If you have any question, please feel free to contact us.

Product Categories : Active Pharmaceutical Ingredients

Product Images
  • Pulmonary Hypertension Treatment Ambrisentan 177036-94-1
Email to this supplier
  • *Subject:
  • *Messages:
    Your message must be between 20-8000 characters
Copyright © 2018 Taizhou Volsen Chemical Co., Ltd. All rights reserved.
Communicate with Supplier?Supplier
Amy Cheng Ms. Amy Cheng
What can I do for you?